1154-P: Increasing Awareness and Identification of Maturity-Onset Diabetes of the Young (MODY) in a Pediatric Diabetes Clinic

by sugaradmin



Introduction and Objective: MODY is frequently misdiagnosed, but accurate diagnosis can afford alternate management options. Prevalent barriers to MODY identification include lack of familiarity with MODY testing guidelines and insurance denial for testing. We launched a quality improvement (QI) project in 2022 at a pediatric, tertiary care center which aimed to: (1) increase the number of MODY tests ordered on pancreatic autoantibody (PAA)-negative patients diagnosed with diabetes and (2) increase provider awareness of MODY.Methods: A monthly electronic health record report was generated with patients diagnosed with PAA-negative new-onset diabetes mellitus (NODM) in the prior 3 months with an appointment scheduled in the reporting month. For each patient, a templated email was sent to the provider before the clinic visit that (1) noted the PAA-negative status, (2) outlined MODY testing criteria, and (3) provided instructions for ordering MODY testing, if indicated. The number of MODY tests ordered was tracked and analyzed on a control chart. Provider awareness of MODY and feedback on the process was assessed using 2 REDCap surveys in 5/2023 and 3/2024.Results: Among PAA-negative patients with NODM diagnosed within 365 days of a visit in the calendar year (CY) quarter, the average percentage of MODY tests ordered increased from 1.97% at baseline (CY Q3’20 – Q4’21) to 8.20% (CY Q1’22 – Q1’24). Providers indicating that they were “extremely” familiar with criteria for MODY testing increased from 0% to 17%. Among responding providers who received an email (n=6), all felt that the email increased their likelihood of sending MODY testing, with 50% describing that it did so “quite a bit” or “extremely.”Conclusion: An email to providers of PAA-negative patients with NODM was associated with an increase in MODY testing and awareness of MODY in a pediatric diabetes clinic. This simple intervention has potential for expansion to other programs to improve detection of MODY.

Disclosure

R.J. Kreienkamp: None. J. Ruiz: Research Support; Dexcom, Inc. S.F. Schlegel: None. O.R. Sterns: None. T.K. Maxwell: None. C. Cherella: Consultant; Intellia Therapeutics. E. Rhodes: Other Relationship; National Institutes of Health.

Funding

National Institute of Health (T32DK007699 (RJK, JLR))



Source link